Crown Bioscience Increases APAC Capacity with New Facility in Zhongshan, China
Crown Bioscience, a JSR Life Sciences company, today announces the opening of a new oncology-focused research facility in Zhongshan, China to satisfy increased customer demand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005098/en/
CrownBio's New Zhongshan, China Facility (Photo: Business Wire)
In addition to the Company’s four facilities across the US and Europe, CrownBio’s existing APAC footprint currently includes three sites located in Beijing, Taicang, and Suzhou, as well as one in Taiwan. Once completed, this new building will add more than 2,000m2 of new vivarium space to support CrownBio’s in vivo oncology platforms, helping satisfy predicted near-term growth.
CrownBio’s world-leading products and services are used by pharmaceutical and biotech customers across APAC, North America, and Europe to accelerate and de-risk their drug discovery programs. With the significant and continued growth of CrownBio’s client base, the Zhongshan facility has been purpose built to meet expanding study needs.
The research and drug development facility features BSL-2 laboratories and will include a state-of-the-art ABSL-2 vivarium. Initial capabilities will focus on expanding cell line-derived xenograft model availability and study throughput, with an increased roster of cutting edge, translational oncology models becoming available. Full operational capacity is expected in early 2021.
“The establishment of our new Zhongshan facility demonstrates our continued commitment to our clients, to provide sustained rapid study initiation combined with robust cost-effectiveness,” said John Gu, chief operating officer at CrownBio. “Through our growth, we can more fully support our clients in their goals of more rapid and efficient cancer drug development”.
A site opening event and ribbon cutting ceremony will take place on October 30th 2020.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
● https://www.jsrlifesciences.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005098/en/
Contact information
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
pr@crownbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vedanta Resources Launches CopperTech Metals to Bolster U.S. Copper Security and Advance Technology and Infrastructure Transformation6.11.2025 18:45:00 EET | Press release
Vedanta Resources Limited ("Vedanta") today announced the launch of CopperTech Metals Inc. ("CopperTech" or the "Company"), a U.S.-domiciled company with a mission to 'Power the Copper Century' and to bolster America's copper security needs while capitalizing on surging copper demand driven by artificial intelligence, data center expansion, grid modernization, defense technologies and industrial onshoring requirements. CopperTech will1 own and operate the Konkola Copper Mines in Zambia, one of the highest-grade copper producing assets in the world with proven cobalt reserves. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106537189/en/ CopperTech intends to build on the existing $3 billion investment made by Vedanta Resources Limited in the Konkola Copper Mines – which included construction of a deep mine shaft, a smelter and a concentrator, and engaging in general mine development – and intends to invest an additional $1
NJ Bio Bridges the Translation Research Gap with the Asset Purchase and Integration of L2P ® Services6.11.2025 18:11:00 EET | Press release
NJ Bio, Inc., a premier contract research and clinical manufacturing service provider in Princeton, New Jersey has announced the asset purchase and full integration of the research services of L2P Research Labs® (“Lab to Pharmacy”), further expanding its service portfolio, and bridging the translational research gap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106703527/en/ NJ Bio, Inc. now offers translational research services after completing asset purchase and full integration of the services of L2P® Research Labs, enhancing the discovery-to-development pipeline Currently, the attrition rate of biological molecules moving past phase 1 clinical trials is very high and the way to overcome this challenge is through translational research. NJ Bio specializes in preclinical and early-phase clinical research and development, with a primary focus on ADCs, bioconjugation, custom synthesis, oligonucleotides, and mRNAs. Howe
DevvStream Reports Fiscal Year 2025 Results and Advances Digital-Asset and Tokenization Strategy6.11.2025 18:01:00 EET | Press release
DevvStream Corp. (Nasdaq: DEVS) (“DevvStream” or the “Company”), a leading carbon management and environmental-asset monetization firm, today announced financial results for its fiscal year ended July 31, 2025, and provided an update on strategic initiatives designed to enhance liquidity, expand technology capabilities, and position the Company for scalable, acquisition-driven growth. Fiscal 2025 Highlights Completed Nasdaq listing and de-SPAC transaction, establishing DevvStream as one of the few publicly traded pure plays in carbon and renewable-energy asset monetization. Closed initial $10 million tranche under the Helena $300 million convertible-note facility, providing liquidity to launch the Company’s digital-asset treasury. Reported initial revenue as the Company begins monetizing its environmental-asset pipeline. Successfully completed strategic investments and partnerships that expand DevvStream’s reach across carbon, renewable-energy, and environmental-credit markets. Strengt
BST Global Launches 2026 AI + Data Impact Survey for the AEC Industry6.11.2025 17:41:00 EET | Press release
BST Global, the leading provider of AI-powered project intelligence™ solutions for the AEC industry, has launched its second annual global AI + Data Survey. Seeking insights from technology and data leaders of architecture, engineering and environmental consultancies around the world, the survey will be available until 11:59 p.m. ET, December 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105615222/en/ BST Global, the leading provider of AI-powered project intelligence™ solutions for the AEC industry, has launched its second annual global AI + Data Survey. Seeking insights from technology and data leaders of architecture, engineering and environmental consultancies around the world, the survey will be available until 11:59 p.m. ET, December 31, 2025. Conducted in partnership with BST Global’s AI + Data Consortium and the American Council of Engineering Companies' (ACEC) Technology Committee, the survey focuses s
Scientist.com Wins Supplier Management Excellence Award at B2B Ecommerce Awards6.11.2025 16:43:00 EET | Press release
Scientist.com, the leading AI-enabled R&D orchestration platform for the life sciences, has been named the winner of the Supplier Management Excellence award at the prestigious B2B Ecommerce Awards. The honor recognizes organizations that set new standards in supplier network innovation, integration, and performance to deliver superior customer value. “Winning this award is a tremendous honor and a testament to our team’s relentless focus on simplifying and accelerating R&D,” said Andrew Nashed, VP, Supplier Relations at Scientist.com. “Our platform automates and optimizes the complex process of supplier management, enabling scientists to focus on innovation while we handle compliance, integration, and operational efficiency.” Scientist.com was recognized for its industry-leading approach to building and managing the world’s largest network of scientific service providers. Its technology-driven platform connects pharmaceutical, biotech, and academic researchers with over 6,000 pre-qual
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom